IRIS
SPAGNOLO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.169
Totale 3.169
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 3.169
Totale 3.169
Salva come PNG Salva come JPEG
Città #
Genova 1.898
Genoa 654
Rapallo 518
Vado Ligure 76
Bordighera 23
Totale 3.169
Salva come PNG Salva come JPEG
Nome #
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry 171
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 143
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. 140
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients 138
Analisi fenotipica e funzionale dell’infiltrato linfocitario in biopsie di metastasi di melanoma, in pazienti in terapia con farmaci a bersaglio molecolare e/o inibitori dei checkpoint immunologici 138
Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148 129
Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations 128
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function 127
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. 120
Regenerative surgery for the definitive surgical repair of enterocutaneous fistula 119
Regenerative surgery for the definitive repair of a vasculitic nonhealing ulcer using platelet-derived growth factors and noncultured autologous cell suspension 106
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 103
HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition 103
Regenerative surgery for the definitive repair of chronic ulcers: a series of 34 cases treated with platelet-derived growth factors. 87
Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations [Oncotarget. 2018; 9:5691-5702]doi 10.18632/oncotarget.23204 85
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review 84
Regenerative Medicine for the Treatment of Teno-desmic Injuries of the Equine. A Series of 150 Horses Treated with Platelet-derived Growth Factors 83
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization 75
Solar radiation as a risk factor for cutaneous melanoma: Review 72
The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study 67
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients 67
Current State of Target Treatment in BRAF Mutated Melanoma 67
Insights into genetic susceptibility to melanoma by gene panel testing: Potential pathogenic variants in acd, atm, bap1, and pot1 64
The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival 59
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab 59
Association of vacuum-assisted closure and platelet gel for the definitive surgical repair of an enterocutaneous fistula: a case report. 53
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 53
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape 52
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient 49
Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants 39
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications 35
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 35
How to make immunotherapy an effective therapeutic choice for uveal melanoma 33
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting 29
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 26
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma 23
Molecular Assessment in Patients with Melanoma: When and Why? 23
How I perform fertility preservation in breast cancer patients 21
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup 20
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 18
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis 17
Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis 14
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 13
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma 13
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 11
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study 10
BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma 10
Primary endobronchial melanoma: a case report and clinical management indications 10
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion 9
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma 9
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort 8
Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma 8
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 8
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 8
Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib 8
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial 7
Sun exposure and melanoma prognostic factors 7
The treatment of advanced melanoma: Current approaches and new challenges 7
Management of immune-related adverse events during treatment with immune checkpoint inhibitors 7
Uveal melanoma 6
Upcoming strategies for the treatment of metastatic melanoma 6
mAbs targeting CTLA-4 and clinical outcomes 5
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 5
Uveal melanoma 5
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 5
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy 5
Association between PD-1 single nucleotide gene variants and the risk of metastatic melanoma 4
Hedgehog Inhibitors beyond Clinical Complete Response in Basal Cell Carcinoma: Should i Stop or Should i Go? 4
Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 4
Treatment of metastatic uveal melanoma with intravenous fotemustine 4
Current status and perspectives in immunotherapy for metastatic melanoma 4
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma 4
Combined robotic inguinal and iliac-obturator lymphadenectomy for stage III skin cancers: Surgical technique and preliminary results 3
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 3
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial 3
Update on Metastatic Uveal Melanoma: Progress and Challenges 3
Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program 3
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial 3
The role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma 3
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study 3
Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study 3
Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy 3
The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts 2
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 2
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 2
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 2
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review 2
Effect of age on melanoma risk, prognosis and treatment response 2
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma 2
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study 2
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective 2
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial 2
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel 2
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study 2
Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study 2
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study 2
Binimetinib for the treatment of NRAS-mutant melanoma 2
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 2
No impact of NRAS mutation on features of primary and metastatic melanoma or on outcomes of checkpoint inhibitor immunotherapy: An italian melanoma intergroup (IMI) study 2
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? 2
Totale 3.354
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.875
article - articoli 14.258
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 313
Totale 29.446
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020619 0 17 16 37 44 71 104 54 72 102 83 19
2020/2021358 22 23 29 46 31 14 27 35 31 48 35 17
2021/2022434 21 21 23 46 21 42 19 81 38 61 13 48
2022/2023628 49 52 6 53 112 96 4 48 92 8 100 8
2023/2024613 12 43 18 82 35 84 21 57 30 29 37 165
2024/2025124 109 15 0 0 0 0 0 0 0 0 0 0
Totale 3.370